Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab in Solid Tumors With FGFR2b Overexpression
NCT05325866Phase 2Terminated
- Sponsor
- Amgen
- Start
- Sep 2022
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 2 trial of bemarituzumab in solid tumor, sponsored by Amgen. Started Sep 2022; status: terminated.
02
Drugs
bemarituzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05325866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325866.